Business Description
Harbin Medisan Pharmaceutical Co Ltd
ISIN : CNE1000032V9
Share Class Description:
SZSE:002900: Class ACompare
Compare
Traded in other countries / regions
002900.China IPO Date
2017-09-22Description
Harbin Medisan Pharmaceutical Co Ltd is the pharmaceutical manufacturing company. It is engaged in the research, development, manufacturing and sales of chemical preparations. The main products are oxiracetam injection, mirtazapine tablets, valsartan dispersible tablets, injection brain drugs such as protein hydrolysate, glucose injection and sodium chloride injection. The company is also involved in research, development, production and sales of medical devices.
Financial Strength
4/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| Cash-To-Debt | 1.25 | |||||
| Equity-to-Asset | 0.6 | |||||
| Debt-to-Equity | 0.43 | |||||
| Debt-to-EBITDA | 11.38 | |||||
| Piotroski F-Score | 2/9 | |||||
| Altman Z-Score | 2.05 | |||||
| Beneish M-Score | -2.65 | |||||
| WACC vs ROIC | ||||||
Growth Rank
1/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| 3-Year Revenue Growth Rate | -2 | |||||
| 3-Year EBITDA Growth Rate | 22.7 | |||||
| 3-Year FCF Growth Rate | -23.1 | |||||
| 3-Year Book Growth Rate | 6.4 |
Momentum Rank
7/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| 5-Day RSI | 56.09 | |||||
| 9-Day RSI | 51.32 | |||||
| 14-Day RSI | 50.86 | |||||
| 6-1 Month Momentum % | -25.72 | |||||
| 12-1 Month Momentum % | -23.12 |
Liquidity Ratio
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| Current Ratio | 1.36 | |||||
| Quick Ratio | 1.16 | |||||
| Cash Ratio | 1 | |||||
| Days Inventory | 155.87 | |||||
| Days Sales Outstanding | 36.22 | |||||
| Days Payable | 134.74 |
Dividend & Buy Back
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| Dividend Yield % | 0.96 | |||||
| Dividend Payout Ratio | 0.71 | |||||
| 3-Year Dividend Growth Rate | -29.1 | |||||
| Forward Dividend Yield % | 0.96 | |||||
| 5-Year Yield-on-Cost % | 0.25 | |||||
| Shareholder Yield % | -1.14 |
Profitability Rank
5/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| Gross Margin % | 58.32 | |||||
| Operating Margin % | -0.49 | |||||
| Net Margin % | 4.88 | |||||
| FCF Margin % | -30.24 | |||||
| ROE % | 2.52 | |||||
| ROA % | 1.54 | |||||
| ROIC % | -0.19 | |||||
| ROC (Joel Greenblatt) % | 7.85 | |||||
| ROCE % | 3.11 | |||||
| Years of Profitability over Past 10-Year | 10 |
GF Value Rank
8/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| PE Ratio | 62.12 | |||||
| PE Ratio without NRI | 74.89 | |||||
| Shiller PE Ratio | 17.6 | |||||
| PS Ratio | 3 | |||||
| PB Ratio | 1.55 | |||||
| Price-to-Tangible-Book | 1.65 | |||||
| EV-to-EBIT | 37.69 | |||||
| EV-to-EBITDA | 37.69 | |||||
| EV-to-Revenue | 2.81 | |||||
| EV-to-FCF | -8.81 | |||||
| Price-to-Projected-FCF | 2.35 | |||||
| Price-to-Graham-Number | 2.35 | |||||
| Price-to-Net-Current-Asset-Value | 32 | |||||
| Earnings Yield (Greenblatt) % | 2.65 | |||||
| FCF Yield % | -9.88 | |||||
| Forward Rate of Return (Yacktman) % | 2.82 |
Historical Operating Revenue by Business Segment
Historical Operating Revenue by Geographic Region
Guru Trades
See DetailsInsider Trades
See DetailsPeter Lynch Chart
Performance
Dividend
Log
Bar
Annualized Return % Â
Total Annual Return % Â
Harbin Medisan Pharmaceutical Co Ltd Executives
DetailsAnalyst Estimate
Key Statistics
| Name | Value | ||
|---|---|---|---|
| Revenue (TTM) (Mil ¥) | 1,091.457 | ||
| EPS (TTM) (Â¥) | 0.17 | ||
| Beta | 2.01 | ||
| Volatility % | 35.88 | ||
| 14-Day RSI | 50.86 | ||
| 14-Day ATR (Â¥) | 0.612032 | ||
| 20-Day SMA (Â¥) | 10.484 | ||
| 12-1 Month Momentum % | -23.12 | ||
| 52-Week Range (Â¥) | 6.74 - 15.49 | ||
| Shares Outstanding (Mil) | 316.39 |
Piotroski F-Score Details
Year:
| Component | Result | ||
|---|---|---|---|
| Piotroski F-Score | 2 | ||
| Positive ROA | |||
| Positive CFROA | |||
| Higher ROA yoy | |||
| CFROA > ROA | |||
| Lower Leverage yoy | |||
| Higher Current Ratio yoy | |||
| Less Shares Outstanding yoy | |||
| Higher Gross Margin yoy | |||
| Higher Asset Turnover yoy |
Harbin Medisan Pharmaceutical Co Ltd Filings
| Filing Date | Document Date | Form | ||
|---|---|---|---|---|
| No Filing Data | ||||
Harbin Medisan Pharmaceutical Co Ltd Stock Events
| Event | Date | Price(Â¥) | ||
|---|---|---|---|---|
| No Event Data | ||||
Harbin Medisan Pharmaceutical Co Ltd Frequently Asked Questions
What is Harbin Medisan Pharmaceutical Co Ltd(SZSE:002900)'s stock price today?
The current price of SZSE:002900 is ¥10.56. The 52 week high of SZSE:002900 is ¥15.49 and 52 week low is ¥6.74.
When is next earnings date of Harbin Medisan Pharmaceutical Co Ltd(SZSE:002900)?
The next earnings date of Harbin Medisan Pharmaceutical Co Ltd(SZSE:002900) is .
Does Harbin Medisan Pharmaceutical Co Ltd(SZSE:002900) pay dividends? If so, how much?
The Dividend Yield %  of Harbin Medisan Pharmaceutical Co Ltd(SZSE:002900) is 0.96% (As of Today), Highest Dividend Payout Ratio of Harbin Medisan Pharmaceutical Co Ltd(SZSE:002900) was 10.67. The lowest was 0.07. And the median was 1.31. The  Forward Dividend Yield % of Harbin Medisan Pharmaceutical Co Ltd(SZSE:002900) is 0.96%. For more information regarding to dividend, please check our Dividend Page.
Press Release
| Subject | Date | |||
|---|---|---|---|---|
| No Press Release | ||||
Survey
We'd love to learn more about your experiences on GuruFocus.com and how we can improve!
Take Survey
Follow Us
Disclaimers